HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug STRO-004 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called STRO-004 in adults with advanced solid tumors that have not responded to standard treatments. The study has three parts: finding a safe dose of STRO-004 alone, testing that dose in more patients, and combining STRO-004 with another c…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated May 26, 2026 04:19 UTC
-
New drug GTAEXS617 enters human trials for tough cancers
Disease control Recruiting nowThis study tests a new drug called GTAEXS617 in 230 adults with advanced solid tumors, including lung, breast, ovarian, pancreatic, and head and neck cancers. The goal is to check the drug's safety, how the body processes it, and whether it can shrink tumors. Participants must ha…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1, PHASE2 • Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 04:18 UTC
-
New drug combo aims to shrink head and neck tumors
Disease control Recruiting nowThis study tests whether adding an experimental drug (fianlimab) to a standard immunotherapy (cemiplimab) works better than the standard drug alone for people with head and neck cancer that has returned or spread. About 120 adults whose tumors show a specific protein (PD-L1) will…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 04:18 UTC
-
Can Six-Day radiation beat Five-Day for head and neck cancer?
Disease control Recruiting nowThis study looks at whether giving radiation therapy six days a week (instead of the usual five) can better control head and neck cancer in people who start treatment more than six weeks after surgery. About 75 adults with certain types of head and neck cancer will be randomly as…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated May 26, 2026 04:12 UTC
-
New hope for Hard-to-Treat cancers: experimental drug MT-4561 enters human trials
Disease control Recruiting nowThis study tests an experimental drug called MT-4561 in people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have tried at least one prior therapy. The main goals are to find a safe dose and check for early signs of tumor shrinkage. About 27 adults will…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1, PHASE2 • Sponsor: Tanabe Pharma America, Inc. • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
New hope for tough cancers: experimental drug VMD-928 enters human trials
Disease control Recruiting nowThis study tests an experimental drug called VMD-928, taken as a pill, either alone or with another drug (pembrolizumab), in people with advanced solid tumors or lymphoma that have stopped responding to standard treatments. The goal is to find a safe dose and see if it can shrink…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1, PHASE2 • Sponsor: VM Oncology, LLC • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
New drug EXS74539 enters first human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called EXS74539 in about 40 adults with certain solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to find the safest dose and check for side effects. Researchers will also watch for any signs that the dru…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1 • Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
New drug duo aims to shrink head and neck tumors before surgery
Disease control Recruiting nowThis phase 2 trial tests whether giving two drugs—ficerafusp alfa and pembrolizumab—before surgery can shrink tumors in people with advanced head and neck cancer. The study enrolls 32 adults with newly diagnosed, resectable cancer that has not spread. The goal is to see if the co…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
Experimental combo offers hope for Hard-to-Treat head and neck cancer
Disease control Recruiting nowThis early-stage trial tests whether giving a second round of radiation therapy along with a drug called chidamide is safe for people whose head and neck cancer has come back after previous radiation. The study involves 6 adults aged 18 to 75 with a specific type of cancer. The m…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New drug EPI-326 enters first human tests for tough cancers
Disease control Recruiting nowThis early-phase study tests a new drug called EPI-326 in about 110 people with advanced lung cancer (with a specific EGFR gene change) or head/neck cancer. The main goal is to check safety and find the best dose. Participants receive the drug and are monitored for side effects a…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1 • Sponsor: EpiBiologics • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new experimental drug (LB-LR1109) alone or combined with atezolizumab in people with advanced solid tumors, including lung, head and neck, kidney, bladder, and skin cancers. The main goals are to find safe doses and understand side effects. About 76…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1 • Sponsor: LG Chem • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Can less radiation after head and neck cancer surgery keep patients cancer-free?
Disease control Recruiting nowThis study looks at whether people with advanced head and neck cancer who had a good response to chemo-immunotherapy before surgery can safely receive less radiation after surgery. The goal is to keep cancer from coming back while improving quality of life. About 50 adults who me…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New drug cocktail aims to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called XL092, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their gro…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated May 19, 2026 11:46 UTC
-
New drug combo aims to shrink head and neck tumors before surgery
Disease control Recruiting nowThis early-phase trial tests whether combining two drugs (GV20-0251 and sintilimab) before surgery is safe and can shrink tumors in adults with advanced head and neck cancer. Nine participants will receive two cycles of the drug combo, then undergo surgery. The study focuses on s…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated May 07, 2026 18:40 UTC
-
New scan spots hidden cancer spread before surgery
Diagnosis Recruiting nowThis study tests a special PET/CT scan that targets cells helping cancer spread, to see if it can find early signs of lymph node involvement in head and neck cancer. About 20 adults with operable head and neck cancer and at least one known lymph node metastasis will receive the s…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE2 • Sponsor: John O. Prior • Aim: Diagnosis
Last updated May 22, 2026 14:04 UTC
-
App-Based Check-Ins may help cancer patients keep weight on during radiation
Symptom relief Recruiting nowThis study tests whether using a smartphone app to regularly report symptoms can help doctors catch problems early in head and neck cancer patients receiving radiation or chemoradiation with the goal of cure. The main focus is on preventing significant weight loss three months af…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: NA • Sponsor: Centre Henri Becquerel • Aim: Symptom relief
Last updated May 26, 2026 04:20 UTC
-
Could your cells hold the key to a new cancer therapy?
Knowledge-focused Recruiting nowThis study is gathering tumor tissue and blood cells from 200 adults with advanced solid tumors like colorectal, lung, or pancreatic cancer. The goal is to learn how often certain genetic changes occur and to store participants' own immune cells for possible future use in making …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Sponsor: A2 Biotherapeutics Inc. • Aim: Knowledge-focused
Last updated May 22, 2026 14:02 UTC